Inag-Nievergelt AG joins BKW / BKW expands its building technology installation business
plus
Actualités sur Économie
Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that Victoza® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal ...
plusRichmont Mines Added to the S&P/TSX Global Mining Index and the S&P/TSX Global Gold Index
Toronto (ots/PRNewswire) - Richmont Mines Inc. (TSX - NYSE MKT: RIC) ("Richmont" or the "Corporation") is pleased to announce that it will be added to the S&P/TSX Global Mining Index and the S&P/TSX Global Gold Index, effective after the close of trading on Friday, June 17, 2016. S&P Dow Jones Canadian Index Services announced this addition on June 10, 2016, following ...
plusFaster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts: 293-OR, 240-OR Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that ...
plusAuRico Metals Provides Management Update
Toronto (ots/PRNewswire) - AuRico Metals Inc. (TSX: AMI) ("AuRico" or the "Company") is pleased to announce the appointment of John Miniotis as Vice President, Corporate Development and the appointment of David Flahr as Vice President, Finance. Both appointments are effective June 13, 2016. Mr. Miniotis is joining AuRico Metals from Lundin Mining where he played a leading role advancing their M&A (mergers and ...
plusAtradius: World Economy 'Slower for Longer', Warns for Insolvencies in Eurozone Periphery
Amsterdam (ots/PRNewswire) - The Atradius outlook for global economic growth is 'slower for longer', with five primary downside risks that could drag down the economic and insolvency outlooks. (Logo: http://photos.prnewswire.com/prnh/20150513/743985 ) While the turbulence experienced in the first months of 2016 has subsided the underlying issues persist. Low commodity ...
plusMerck in Agreement with HAPPYneuron to Offer First-of-its-Kind e-Health Solution for People Living with Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Agreement provides Merck with exclusive license to cognitive remediation training programs - HAPPYneuron will be available for inclusion in Merck's MSdialog platform for use with Rebif® (interferon beta-1a) Merck, a leading science and technology company, announced today that ...
plusSemaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults With Type 2 Diabetes
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
plusSuccessful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
Paris (ots/PRNewswire) - Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined ...
plusTresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
plusShire Pharmaceuticals Group Plc
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
plusEQS-Adhoc: SANDPIPER Digital Payments AG announces annual figures for 2015
EQS Group-Ad-hoc: Sandpiper Digital Payments AG / Key word(s): Final Results/AGM/EGM SANDPIPER Digital Payments AG announces annual figures for 2015 10.06.2016 / 20:00 Release of an ad hoc announcement pursuant to Art. 18 KR. The issuer is solely responsible for the content of this announcement. 470853 10.06.2016 ...
plusViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
London (ots/PRNewswire) - Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral ...
plusUCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...
plusHydro-Québec's Strategic Plan 2016-2020 - Hydro-Québec is Poised to Attract Data Centres
Montréal (ots/PRNewswire) - Hydro-Québec has announced a move to attract data centres to Québec. The decision is in line with one of the objectives outlined in its Strategic Plan 2016-2020, namely to lay the groundwork to double the company's revenue over the next 15 years. "The global data centre market is rapidly growing and we have what it takes to be at the ...
plusDGAP-News: LION E-Mobility AG: Join Venture 'TÜV SÜD Battery Testing GmbH' receives grant in highly remunerated EU funding project
DGAP-News: LION E-Mobility AG / Key word(s): Incoming Orders/Joint Venture LION E-Mobility AG: Join Venture 'TÜV SÜD Battery Testing GmbH' receives grant in highly remunerated EU funding project 08.06.2016 / 14:34 The issuer is solely responsible for the content of this announcement. 470161 08.06.2016 ...
plusUCB Commitment to Addressing Real World Patient Needs on Display at the Annual European Congress of Rheumatology (EULAR 2016)
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
plusDebiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
plusD+H Joins Blockchain Panel at EBAday Conference
New York (ots/PRNewswire) - DH Corporation (http://dh.com/) (TSX: DH) ("D+H"), a leading provider of technology solutions to financial institutions globally, today announced that Gene Neyer, D+H's head of product, global payments, will join a panel titled "How Mainstream Can Blockchain Be?" at EBAday, a leading forum covering the key trends impacting the payments industry, on June 7 in Milan, Italy. The panel, which ...
plusNovo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th ...
plusDGAP-News: LION E-Mobility AG: LION Smart GmbH and consortium partners receive grant in highly remunerated EU funding project
DGAP-News: LION E-Mobility AG / Key word(s): Incoming Orders/Miscellaneous LION E-Mobility AG: LION Smart GmbH and consortium partners receive grant in highly remunerated EU funding project 06.06.2016 / 08:00 The issuer is solely responsible for the content of this announcement. 469249 06.06.2016 ...
plusJSS Medical Research Establishes Its Presence in Europe
Montreal (ots/PRNewswire) - - JSS Medical Research, an international contract research organization active in over 20 countries acquires Bonne Santé in Poland as catalyst for European expansion JSS Medical Research Inc., an International Contract Research Organization (CRO) with offices in Canada, Latin America and Asia/Pacific, announced the acquisition of Bonne Santé, a Polish CRO, to accelerate the expansion into ...
plusEQS-Adhoc: Jungfraubahn Holding AG: Jürg Lauper to retire
EQS Group-Ad-hoc: Jungfraubahn Holding AG / Key word(s): Change of Personnel Jungfraubahn Holding AG: Jürg Lauper to retire 04.06.2016 / 20:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 469227 04.06.2016 ...
plusMerck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) Merck, a leading science and technology company, jointly announced with ...
plusEANS-Adhoc: Semperit AG Holding / Partial award against Siam Sempermed Corporation Ltd. (SSC) in arbitration proceedings regarding restoration of transparency, access to books of accounts, as well as to premises and factories
issuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wien phone: +43 1 79 777-210 FAX: +43 1 79 777-602 mail: investor@semperitgroup.com WWW: www.semperitgroup.com sector: Synthetics & Plastics ISIN: AT0000785555 indexes: WBI, ATX Prime, ViDX, Prime Market, ATX Global Players stockmarkets: official market: Wien ...
plusEANS-Adhoc: S IMMO AG / S IMMO intends to sell part of its German residential portfolio
issuer: S IMMO AG Friedrichstraße 10 A-1010 Wien phone: +43(0)50100-27550 FAX: +43(0)050100-927559 mail: office@simmoag.at WWW: www.simmoag.at sector: Real Estate ISIN: AT0000652250 indexes: ATX Prime, IATX stockmarkets: official market: Wien language: English ...
plusSequa Petroleum N.V. General Meeting Results 3 June 2016
London (ots/PRNewswire) - The Company confirms that at its General Meeting held on 3 June in Amsterdam, all resolutions were duly passed. Contacts: Jacob Broekhuijsen - CEO +44(0)203-728-4450 or ...
plusEQS-Adhoc: shaPE Capital AG in liquidation - Annual report 2015, further CHF 10 per share distribution to shareholders, and invitation to ordinary shareholder meeting 2016
EQS Group-Ad-hoc: shaPE Capital AG / Key word(s): Final Results/AGM/EGM shaPE Capital AG in liquidation - Annual report 2015, further CHF 10 per share distribution to shareholders, and invitation to ordinary shareholder meeting 2016 03.06.2016 / 09:45 Release of an ad hoc announcement pursuant to Art. 53 KR. The ...
plusThree-year Data Show Early Response to Saxenda® Resulted in Improvements in Weight Loss and Cardiometabolic Risk Factors
Gothenburg, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster# PP3.09 Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) ...
plusEANS-Adhoc: ams AG / ams' Annual General Meeting approves all voting items on the agenda
issuer: ams AG Tobelbader Strasse 30 A-8141 Unterpremstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com sector: Technology ISIN: AT0000A18XM4 indexes: stockmarkets: official dealing: SIX Swiss Exchange language: English ...
plus
Précédent193194195196197198199200201202Suivant